Skip to main content
. 2015 Mar 15;6(2):245–258. doi: 10.4239/wjd.v6.i2.245

Table 3.

Changes of the lipid metabolism parameters after 3-mo of treatment

Parameter Patients with T2DM and CAN (n = 81)
1st group 2nd group 3rd group 4th group 5th group
(n = 15) (n = 21) (n = 12) (n = 18) (n = 15)
LDL cholesterol -8.3 ± 1.4 -12.8 ± 1.9 -7.6 ± 1.0d -14.2 ± 1.8ah -33.1 ± 2.4cfil
HDL cholesterol 4.1 ± 1.0 7.1 ± 0.5a 5.7 ± 0.6 7.8 ± 0.7bg 13.9 ± 1.3cfil
ТG -8.3 ± 1.2 -35.4 ± 2.6c -13.3 ± 3.4f -9.3 ± 1.1f -27.9 ± 3.9chl
TC -6.7 ± 1.0 -8.2 ± 1.1 -7.1 ± 1.2 -10.7 ± 1.3ag -27.2 ± 1.9cfil

The results are presented as % change from baseline, (Δ%, Mean ± SEM);

a

P < 0.05,

b

P < 0.01,

c

P < 0.001 - compared to 1st group;

d

P < 0.05,

f

P < 0.001 - compared to 2nd group;

g

P < 0.05,

h

P < 0.01,

i

P < 0.001 - compared to 3rd group;

l

P < 0.001 - compared to 4th group. T2DM: Type 2 diabetes mellitus; CAN: Cardiac autonomic neuropathy; LDL cholesterol: Low density lipoprotein cholesterol; HDL cholesterol: High density lipoprotein cholesterol; ТG: Triglycerides; TC: Total cholesterol.

HHS Vulnerability Disclosure